Heart Disease and Diabetes

Cardiometabolic Health: Future of Care or Detracting from Endocrinology?

November 25, 2020

In this 3-part feature series, an endocrinologist, a cardiologist, and an internist tackle the topic of who should be in charge of treating patients with diabetes and whether the creation of a cardiometabolic specialty is a worthwhile endeavor.

Analysis Indicates Semaglutide Reduces MACE Regardless of Triglyceride Levels

November 23, 2020

An analysis of data from a pair of major trials indicates use of semaglutide was associated with a reduction in MACE regardless of a patient's baseline triglyceride levels.

Muthiah Vaduganathan, MD: Key Takeaways from Sotagliflozin Data

November 21, 2020

A cardiologist from Brigham and Women's Hospital offers his thoughts on the results of phase 3 SCORED and SOLOIST trials, which examined use of sotagliflozin in patients with type 2 diabetes.

Comparing Cost-Effectiveness of Antidiabetic Therapies with Cardiovascular Benefit

November 19, 2020

Gregory Weiss, MD, examines 4 studies presented at AHA Scientific Sessions 2020 comparing the cost-effectiveness of antidiabetic agents for reducing cardiovascular events.

AHA & AstraZeneca Push for Uptake of SGLT2 Inhibitors with TRANSLATE-HF Program

November 18, 2020

TRANSLATE-HF is a collaborative effort between the AHA and AstraZeneca with the goal of increasing and optimizing SGLT2 inhibitor use in US patients. Hear further insight lead author from the first of 6 TRANSLATE-HF studies, which was presented at AHA 2020.

Deepak Bhatt, MD: Sotagliflozin and Phase 3 Data from AHA 2020

November 17, 2020

Deepak Bhatt, MD, MPH, offers his thoughts on the results of SCORED and SOLOIST as well as diving deeper into the implications of the data for sotagliflozin and SGLT2 inhibitors moving forward.

George Bakris, MD: Cardiovascular Benefits of Finerenone in FIDELIO-DKD

November 17, 2020

George Bakris, MD, offers further insight into the cardiovascular outcomes analysis of FIDELIO-DKD presented at AHA 2020.

Sotagliflozin, a Dual SGLT2/1 Inhibitor, Shows Promise in Phase 3 Trials

November 17, 2020

Data from the phase 3 SOLOIST-WHF and SCORED trials suggest sotagliflozin was associated with significant reductions in death from CVD in patients with worsening heart failure and significant reductions in blood glucose levels among patients with moderate to severe kidney impairment.

TRANSLATE-HF: More than 80% of Heart Failure Patients Eligible for Dapagliflozin

November 15, 2020

An analysis of HFrEF patients from the GWTG-HF registry suggests 81% met eligibility criteria for receiving treatment with dapagliflozin.

John McMurray, MD: DAPA-CKD and Cardiorenal Protection

November 14, 2020

Professor John McMurray discusses DAPA-CKD and what insights it provides into the cardiorenal protection seen with dapagliflozin (Farxiga) use in the landmark trial.